A Few Suggestions for Further Research

  • Yusuf YaziciEmail author
  • Emire Seyahi
  • Gulen Hatemi
  • Hasan Yazici


The Editors, to underline the need for more clinical research in Behcet syndrome (BS), discuss, among surely many, some areas in which more work is needed. In this line, we like to draw the readers’ attention to subspecialty-based disease/classification criteria, a prospective approach to give more sound causality aspect to the gene associations we already know, more both clinical and basic science work on the venous wall which recent data indicate is probably quite important in pathogenesis, and reassess the efficacy of drugs we currently use by withdrawal randomized clinical trials.


Clinical research Criteria Gene associations Venous wall Withdrawal randomized trials 


  1. 1.
    Ohno S, Aoki K, Sugiura S, et al. HL-A5 and Behçet’s disease. Lancet. 1973;2(7842):1383–4.CrossRefGoogle Scholar
  2. 2.
    Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behçet’s syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34:244–6.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Madanat WY, Alawneh KM, Smadi MM, et al. The prevalence of Behçet’s disease in the north of Jordan: a hospital-based epidemiological survey. Clin Exp Rheumatol. 2017;35 Suppl 108:S51–4.Google Scholar
  4. 4.
    National Institutes of Health. All of us research program. Accessed 30 Apr 2019.
  5. 5.
    Masatlioglu S, Seyahi E, Tahir Turanli E, et al. A twin study in Behçet’s syndrome. Clin Exp Rheumatol. 2010;28(Suppl 60):S62–6.Google Scholar
  6. 6.
    Karaca M, Hatemi G, Sut N, Yazici H. The papulopustular lesion/arthritis cluster of Behçet’s syndrome also clusters in families. Rheumatology (Oxford). 2012;51:1053–60.CrossRefGoogle Scholar
  7. 7.
    Guedes-Barbosa LS. Oral and genital ulcers in Behçet’s disease. N Engl J Med. 2019;380:e7.CrossRefGoogle Scholar
  8. 8.
    Yazici H, Seyahi E, Hatemi G, et al. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.CrossRefGoogle Scholar
  9. 9.
    Yazici H, Yazici Y. Criteria for Behçet’s disease with reflections on all disease criteria. J Autoimmun. 2014;48-49:104–7.CrossRefGoogle Scholar
  10. 10.
    Yazici H, Yazici Y. Diagnosis and/or classification of vasculitis: different? Curr Opin Rheumatol. 2016;28:3–7.CrossRefGoogle Scholar
  11. 11.
    Fries JF, Hochberg MC, Medsger TA Jr, et al. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1994;37:454–62.CrossRefGoogle Scholar
  12. 12.
    Yazici H. Diagnostic versus classification criteria – a continuum. Bull NYU Hosp Jt Dis. 2009;67:206–8.PubMedGoogle Scholar
  13. 13.
    International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.Google Scholar
  14. 14.
    Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013;21:337–50.CrossRefGoogle Scholar
  15. 15.
    Seyahi E, Gjoni M, Durmaz EŞ, et al. Increased vein wall thickness in Behçet disease. J Vasc Surg Venous Lymphat Disord. 2019;7:677–84.Google Scholar
  16. 16.
    Ambrose N, Pierce IT, Gatehouse PD, et al. Magnetic resonance imaging of vein wall thickness in patients with Behcet’s syndrome. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S99–102.Google Scholar
  17. 17.
    Alibaz-Oner F, Ergelen R, Mutis A et al. Venous vessel wall thickness in lower extremity is increased in male Behcet’s disease patients. Clin Rheumatol. 2019;38(5):1447–1451.CrossRefGoogle Scholar
  18. 18.
    Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet’s syndrome. Rheumatology (Oxford). 2008;47:472–5.CrossRefGoogle Scholar
  19. 19.
    Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.CrossRefGoogle Scholar
  20. 20.
    Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402.PubMedGoogle Scholar
  21. 21.
    Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686–92.CrossRefGoogle Scholar
  22. 22.
    Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542–9.CrossRefGoogle Scholar
  23. 23.
    Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69:2380–5.CrossRefGoogle Scholar
  24. 24.
    Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology. 2018;125(9):1444–51.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Yusuf Yazici
    • 1
    Email author
  • Emire Seyahi
    • 2
  • Gulen Hatemi
    • 3
  • Hasan Yazici
    • 4
  1. 1.School of MedicineNew York UniversityNew YorkUSA
  2. 2.Division of RheumatologyDepartment of Internal Medicine, Istanbul University-CerrahpasaIstanbulTurkey
  3. 3.Department of Internal Medicine, Division of RheumatologyIstanbul University-Cerrahpasa, School of MedicineIstanbulTurkey
  4. 4.Department of MedicineAcademic HospitalIstanbulTurkey

Personalised recommendations